SciDoc Publishers | Open Access | Science Journals | Media Partners

International Journal of Diabetology & Vascular Disease Research (IJDVR)    IJDVR-2328-353X-01-004e

Glycated Albumin: A More Sensitive Predictor of Cardiovascular Disease than Glycated Hemoglobin?

Yoshifumi Saisho

Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

*Corresponding Author

Yoshifumi Saisho
Department of Internal Medicine,
Keio University School of Medicine,
Tokyo, Japan.
Tel: +81-3-3353-1211 Extn: 62383 Fax: +81-3-3359-2745

Article Type: Editorial
Received: October 06, 2013; Published: October 31, 2013;

Citation: Saisho Y (2013) Glycated Albumin: A More Sensitive Predictor of Cardiovascular Disease than Glycated Hemoglobin?. Int J Diabetol Vasc Dis Res. 1(4e), 1-2. doi:

Copyright: Saisho Y© 2013. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Key Words

Glycated Albumin, Glycated Hemoglobin, Cardiovascular Disease, Type 2 Diabetes

Type 2 diabetes is an established risk factor for cardiovascular disease (CVD). Compared to non-diabetic subjects, patients with type 2 diabetes have a 2 to 4-fold increased risk of development of CVD [1]. Intensive glycemic control aiming at HbA1c below 7% has been shown to reduce the risk of development of microvascular disease in patients with type 2 diabetes; however, its effect on CVD was rather modest [2].

Moreover, recent trials aiming to achieve near-normal glycemic control (i.e., HbA1c below 6%) to improve CVD outcomes in patients with type 2 diabetes failed to show a reduction of the primary endpoints (death from CVD, non-fatal myocardial infarct and non-fatal stroke) by intensive glycemic control compared to standard care [3-5]. The findings revealed a modest effect of glycemic control on CVD outcome, and underpinned the importance of avoiding hypoglycemia in the treatment of type 2 diabetes, but also suggested the limitation of HbA1c as a predictor of therapeutic effect on CVD outcome.

Glycated albumin (GA) is a ketoamine which is formed by binding of albumin and glucose by nonenzymatic glycation reaction. Since the turnover of albumin is relatively short, GA reflects the average glucose value in the previous 1 to 2 weeks, whereas HbA1c reflects the average glucose value in the previous 1 to 2 months [6]. Moreover, it has been reported that albumin is more rapidly glycated compared to hemoglobin [7]. Therefore, glycated albumin may reflect glycemic control more sensitively than does HbA1c.

A recently-developed enzyme method for measurement of GA has allowed GA to be more rapidly and easily determined [8]. Recent studies have shown that GA is more strongly correlated with postprandial glycemic excursion compared with HbA1c [9-12]. Since postprandial glycemic excursion has been shown to be a risk factor for CVD [13-14], GA may predict CVD outcome more sensitively than does HbA1c.

This was shown to be the case. It has been reported that GA was more strongly associated with coronary atherosclerosis [15-16]. It has been also reported that GA and GA to HbA1c ratio but not HbA1c predicted the progression of carotid intima-media thickness (IMT) [17]. These findings suggest the usefulness of GA for prediction of CVD. Recently, the usefulness of GA as a predictor of diabetic complications compared with HbA1c was examined in two large-scale studies; the Atherosclerosis Risk in Communities (ARIC) Study and the Diabetes Control and Complications Trial (DCCT). In these studies, GA was significantly associated with microangiopathy; however, its association was comparable to that of HbA1c [18-19]. In DCCT, GA showed no significant association with CVD, whereas HbA1c did [19]. Further prospective study examining the correlation between GA and CVD is warranted.

Although the association between GA and atherosclerosis is explained by postprandial glucose excursion, the underlying mechanism of the association between GA and atherosclerosis remains unclear. It has also been reported that GA itself promotes atherosclerosis through induction of reactive oxygen species and inflammatory chemokines, endothelial damage and vessel wall hypertrophy [20]. To clarify the association between GA and atherosclerosis, further studies to explore the underlying mechanism are also needed.

Another issue with GA is the existence of factors other than plasma glucose level that affect GA level. As HbA1c level is affected by various factors such as anemia and hemoglobinopathy, GA level is also affected by various factors [6, 21]. It has been reported that GA level is decreased with obesity and nephrotic syndrome and increased with liver cirrhosis and hypothyroidism [6, 22]. In clinical settings, since obesity and proteinuria are also associated with increased risk of CVD, the predictive value of GA in those patients needs to be clarified. Nonetheless, in hemodialysis patients, it has been reported that GA more sensitively reflects plasma glucose level and all-cause mortality than does HbA1c [23-24].

In conclusion, GA is a novel glycemic marker which more sensitively reflects postprandial glucose excursion compared with HbA1c. Although GA has been shown to more strongly correlate with atherosclerosis compared with HbA1c in some studies, GA is also affected by various factors other than plasma glucose level, as is HbA1c. Therefore, further studies are warranted to clarify the usefulness of GA in the treatment of type 2 diabetes. Hopefully, a combination of GA and HbA1c would increase the predictive value for CVD, and reducing the GA level would lead to a reduction of CVD in patients with type 2 diabetes.


The author has no conflict of interest.


  1. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. Jun 26 2010;375(9733):2215-2222.
  2. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. Sep 12 1998;352(9131):837-853.
  3. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. Jun 12 2008;358(24):2545-2559.
  4. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. Jun 12 2008;358(24):2560-2572.
  5. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. Jan 8 2009;360(2):129-139.
  6. Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J. 2010;57(9):751-762.
  7. Day JF, Ingebretsen CG, Ingebretsen WR, Jr., Baynes JW, Thorpe SR. Nonenzymatic glucosylation of serum proteins and hemoglobin: response to changes in blood glucose levels in diabetic rats. Diabetes. Jul 1980;29(7):524-527.
  8. Kouzuma T, Usami T, Yamakoshi M, Takahashi M, Imamura S. An enzymatic method for the measurement of glycated albumin in biological samples. Clin Chim Acta. Oct 2002;324(1-2):61-71.
  9. Yoshiuchi K, Matsuhisa M, Katakami N, et al. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J. Jul 2008;55(3):503-507.
  10. Saisho Y, Tanaka K, Abe T, Shimada A, Kawai T, Itoh H. Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes. Diabetol Int. 2011;2:146-153.
  11. Matsumoto H, Murase-Mishiba Y, Yamamoto N, et al. Glycated albumin to glycated hemoglobin ratio is a sensitive indicator of blood glucose variability in patients with fulminant type 1 diabetes. Intern Med. 2012;51(11):1315-1321.
  12. Tanaka C, Saisho Y, Tanaka K, et al. Factors associated with glycemic variability in Japanese patients with diabetes. Diabetol Int. 2013;E-pub ahead of print.
  13. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. Feb 12 2001;161(3):397-405.
  14. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. Jun 1999;22(6):920-924.
  15. Pu LJ, Lu L, Xu XW, et al. Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2006;5:27.
  16. Lu L, Pu LJ, Zhang Q, et al. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis. Oct 2009;206(2):540-545.
  17. Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC. Serum glycated albumin predicts the progression of carotid arterial atherosclerosis. Atherosclerosis. Dec 2012;225(2):450-455.
  18. Selvin E, Francis LM, Ballantyne CM, et al. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care. Apr 2011;34(4):960-967.
  19. Nathan DM, McGee P, Steffes MW, Lachin JM. Relationship of glycated albumin to blood glucose and glycated hemoglobin (HbA1C) values and to retinopathy, nephropathy and cardiovascular outcomes in the DCCT/EDIC Study. Diabetes. Aug 29 2013.
  20. Cohen MP, Ziyadeh FN, Chen S. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J Lab Clin Med. May 2006;147(5):211-219.
  21. Sacks DB. Hemoglobin A1c in diabetes: panacea or pointless? Diabetes. Jan 2013;62(1):41-43.
  22. Koga M, Murai J, Saito H, Matsumoto S, Kasayama S. Effects of thyroid hormone on serum glycated albumin levels: study on nondiabetic subjects. Diabetes Res Clin Pract. May 2009;84(2):163-167.
  23. Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int. May 2008;73(9):1062-1068.
  24. Shafi T, Sozio SM, Plantinga LC, et al. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care. Jun 2013;36(6):1522-1533.

         Indexed in

pubhub   CGS   indexcoop   j-gate   DOAJ   Google_Scholar_logo

       Total Visitors

SciDoc Counter

Get in Touch

SciDoc Publishers
16192 Coastal Highway
Lewes, Delaware 19958
Tel :+1-(302)-703-1005
Fax :+1-(302)-351-7355

Creative Commons License
SciDoc Publishers is licensed under a Creative Commons Attribution 4.0 International License.